

Guyana Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Terms of a Programme

| 1. Country: Guyana | | | | | | | | | | | | | | | |
|---|---|-------------|-------------|-------------------------------------|--------------------|--------------------------------|------------------------------|-------------|-------------|-------------------------------|-----|-----|------------------------------|------------|------------|
| 2. Grant Number: 1518-GUY-25d-X / 15-GUY-08h-Y | | | | | | | | | | | | | | | |
| 3. Date of Decision Letter: 27 May 2015 | | | | | | | | | | | | | | | |
| 4. Date of the Partnership Framework Agreement: 5 February 2015 | | | | | | | | | | | | | | | |
| 5. Programme Title: NVS, IPV Routine | | | | | | | | | | | | | | | |
| 6. Vaccine type: Inactivated Polio Vaccine (IPV) | | | | | | | | | | | | | | | |
| 7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 1 dose(s) per vial, LIQUID | | | | | | | | | | | | | | | |
| 8. Programme Duration²: 2015 - 2018 | | | | | | | | | | | | | | | |
| 9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement): <i>Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i> <table border="1" style="margin: 10px auto; width: 80%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 15%;">2015</th> <th style="width: 15%;">2016</th> <th style="width: 15%;">2017</th> <th style="width: 25%;">Total³</th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td style="text-align: center;">US\$ 20,500</td> <td style="text-align: center;">US\$ 56,500</td> <td style="text-align: center;">US\$ 48,000</td> <td style="text-align: center;">US\$ 125,000</td> </tr> </tbody> </table> | | 2015 | 2016 | 2017 | Total ³ | Programme Budget (US\$) | US\$ 20,500 | US\$ 56,500 | US\$ 48,000 | US\$ 125,000 | | | | | |
| | 2015 | 2016 | 2017 | Total ³ | | | | | | | | | | | |
| Programme Budget (US\$) | US\$ 20,500 | US\$ 56,500 | US\$ 48,000 | US\$ 125,000 | | | | | | | | | | | |
| 10. Vaccine Introduction Grant: US\$ 100,000 | | | | | | | | | | | | | | | |
| 11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴ <table border="1" style="margin: 10px auto; width: 80%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%;">Type of supplies to be purchased with Gavi funds in each year</th> <th style="width: 25%;">2015</th> <th style="width: 25%;">2016</th> </tr> </thead> <tbody> <tr> <td>Number of IPV vaccines doses</td> <td style="text-align: center;">6,600</td> <td style="text-align: center;">18,400</td> </tr> <tr> <td>Number of AD syringes</td> <td style="text-align: center;">7,000</td> <td style="text-align: center;">19,400</td> </tr> <tr> <td>Number of safety boxes</td> <td style="text-align: center;">100</td> <td style="text-align: center;">225</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td style="text-align: center;">US\$20,500</td> <td style="text-align: center;">US\$56,500</td> </tr> </tbody> </table> | Type of supplies to be purchased with Gavi funds in each year | 2015 | 2016 | Number of IPV vaccines doses | 6,600 | 18,400 | Number of AD syringes | 7,000 | 19,400 | Number of safety boxes | 100 | 225 | Annual Amounts (US\$) | US\$20,500 | US\$56,500 |
| Type of supplies to be purchased with Gavi funds in each year | 2015 | 2016 | | | | | | | | | | | | | |
| Number of IPV vaccines doses | 6,600 | 18,400 | | | | | | | | | | | | | |
| Number of AD syringes | 7,000 | 19,400 | | | | | | | | | | | | | |
| Number of safety boxes | 100 | 225 | | | | | | | | | | | | | |
| Annual Amounts (US\$) | US\$20,500 | US\$56,500 | | | | | | | | | | | | | |
| 12. Procurement agency: PAHO | | | | | | | | | | | | | | | |
| 13. Self-procurement: Not applicable | | | | | | | | | | | | | | | |
| 14. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Guyana is encouraged to contribute to vaccine and/or supply costs for IPV. | | | | | | | | | | | | | | | |

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the programme.

³ This is the total amount endorsed by Gavi for 2015 to 2017.

⁴ This is the amount that Gavi has approved.

| | |
|---|------------------------------------|
| 15. Operational support for campaigns: Not applicable | |
| 16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts: | |
| Reports, documents and other deliverables | Due dates |
| Annual Progress Report or equivalent | To be agreed with Gavi Secretariat |
| 17. Financial Clarifications: Not applicable | |
| 18. Other conditions: If Guyana envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Guyana. | |

Signed by,
On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
27 May 2015